Loading clinical trials...

Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction | Clinical Trials | Clareo Health

COMPLETED

Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction

NCT06394986•Moscow Regional Research and Clinical Institute (MONIKI)

View on ClinicalTrials.gov

Summary

This is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a result of a hemodialysis session after a "long" interdialysis interval.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•signed informed consent,
•\> 18 years
•maintenance ("chronic") hemodialysis,
•native arteriovenous fistula,
•arteriovenous fistula volume blood flow ≥1 l/min,
•arteriovenous fistula volume blood flow / cardiac output ratio \< 0.3,
•interdialysis weight gain \<5% of "dry" body weight,
•sufficient hemodialysis dose (eKt/V \> 1.2),
•chronic heart failure (NYHA I-II classes only),
•preserved left ventricular ejection fraction (≥50%),
+4 more criteria

Exclusion Criteria

•hypo/hypertension during or after hemodialysis,
•arrhythmias (except first-degree atrioventricular block) after hemodialysis.

Locations (1)

Moscow Regional Research and Clinical Institute (MONIKI)

Moscow, Russia

Key Dates

Start Date

June 18, 2018

Primary Completion Date

February 18, 2019

Completion Date

February 18, 2019

Last Updated

May 3, 2024

Enrollment

ACTUAL participants

Conditions

Chronic Kidney Disease 5DHeart FailureHeart Failure NYHA Class IHeart Failure NYHA Class II

Interventions

Hemodialysis session

PROCEDURE

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

RECRUITINGNA

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction

Inclusion Criteria

Exclusion Criteria

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Respiratory Virus Infections in Acute Heart Failure